Farther Finance Advisors
RXRX icon

Farther Finance Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Farther Finance Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$53.6K Sell
12,978
-763
-6% -$2.59K ﹤0.01% 3361
2026
Q2 		$50.4K Buy
13,741
+4,778
+53% +$15.9K ﹤0.01% 3240
2026
Q1 		$27.4K Buy
8,963
+1,551
+21% +$5.99K ﹤0.01% 3434
2025
Q4 		$30.3K Sell
7,412
-12,178
-62% -$60.3K ﹤0.01% 3145
2025
Q3 		$95.6K Buy
19,590
+5,388
+38% +$28.3K ﹤0.01% 2062
2025
Q2 		$71.9K Buy
14,202
+6,470
+84% +$31.8K ﹤0.01% 1939
2025
Q1 		$39.4K Sell
7,732
-25
-0.3% -$182 ﹤0.01% 2018
2024
Q4 		$52.4K Buy
7,757
+1,353
+21% +$9.1K ﹤0.01% 1640
2024
Q3 		$42.2K Buy
6,404
+4,091
+177% +$29.3K ﹤0.01% 1742
2024
Q2 		$17.3K Buy
2,313
+135
+6% +$1.18K ﹤0.01% 1831
2024
Q1 		$20.4K Buy
2,178
+2,136
+5,086% +$23.8K ﹤0.01% 1488
2023
Q4 		$414 Buy
+42
New +$299 ﹤0.01% 3030

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
QPBE
Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

Farther Finance Advisors's RXRX Position: Q3 2026 in Review

Farther Finance Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 5.6% in Q3 2026, selling an estimated $2.59K and leaving 12,978 shares worth $53.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3361.

Farther Finance Advisors first reported a position in RXRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $95.6K in Q3 2025. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Farther Finance Advisors held 12,978 shares of Recursion Pharmaceuticals worth $53.6K as of Q3 2026.
  • Farther Finance Advisors sold 763 Recursion Pharmaceuticals shares in Q3 2026, an estimated $2.59K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3361 holding.
  • Farther Finance Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Recursion Pharmaceuticals position peaked at $95.6K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.